MaxCyte Inc（MXCT）股票分析

AI 分析 of MaxCyte Inc (MXCT)

持有

MaxCyte Inc is currently trading at $1.45, which is 69.4% of its 52-week range, indicating it is closer to its high of $1.80 than its low of $0.64. However, the RSI is at 45.41, suggesting that the stock is neither overbought nor oversold. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a gross margin of 63.86%, which is relatively strong. The main risk is the negative net income reported, with a loss of $8.87 million in Q2 2026, indicating ongoing financial struggles. Therefore, while there are some positive indicators, the overall financial performance and lack of clear upward momentum suggest holding rather than buying right now.

估值指标

MaxCyte Inc（MXCT）当前预期市盈率为 0.00，5 年平均预期市盈率为 -13.28。

预期市盈率

高估

5 年均值 P/E

-13.28

当前P/E

0.00

高估

-3.68

低估

-22.87

预期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-9.98

当前EV/EBITDA

-3.07

高估

1.46

低估

-21.43

预期市销率

低估

5 年均值 P/S

9.43

当前P/S

3.86

高估

14.36

低估

4.49

Alphio AI 对 MXCT 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%MXCT

$2.88

情景价格

基

基准

基准 · 50%MXCT

$2.21

情景价格

悲

悲观

悲观 · 25%MXCT

$1.63

情景价格

持有 MXCT 的大户

A

Apollo Global Management, Inc.

+ 持有MXCT

-2.44%

3个月收益率

MXCT 常见问题 —— 由 Alphio AI 解答

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

MaxCyte Inc is currently trading at $1.45, which is 69.4% of its 52-week range, indicating it is closer to its high of $1.80 than its low of $0.64. However, the RSI is at 45.41, suggesting that the stock is neither overbought nor oversold. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a gross margin of 63.86%, which is relatively strong. The main risk is the negative net income reported, with a loss of $8.87 million in Q2 2026, indicating ongoing financial struggles. Therefore, while there are some positive indicators, the overall financial performance and lack of clear upward momentum suggest holding rather than buying right now.